Citadel Advisors
CSBR icon

Citadel Advisors’s Champions Oncology CSBR Stock Holding History

Citadel Advisors’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,100
Closed -$18.2K – 12881
2025
Q1 		$18.2K Buy
2,100
+1,100
+110% +$11.1K ﹤0.01% 13214
2024
Q4 		$8.57K Buy
+1,000
New +$5.03K ﹤0.01% 13677
2024
Q3 		– Sell
-6,100
Closed -$31.5K – 14355
2024
Q2 		$31.5K Sell
6,100
-3,100
-34% -$15.1K ﹤0.01% 12214
2024
Q1 		$45.1K Sell
9,200
-500
-5% -$2.93K ﹤0.01% 12263
2023
Q4 		$52.5K Buy
9,700
+5,100
+111% +$28.4K ﹤0.01% 11735
2023
Q3 		$28.6K Sell
4,600
-75,000
-94% -$474K ﹤0.01% 12309
2023
Q2 		$501K Buy
79,600
+71,300
+859% +$368K ﹤0.01% 7940
2023
Q1 		$33.4K Buy
8,300
+2,800
+51% +$12K ﹤0.01% 12625
2022
Q4 		$24.8K Sell
5,500
-15,700
-74% -$103K ﹤0.01% 12953
2022
Q3 		$159K Buy
+21,200
New +$177K ﹤0.01% 10641

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's CSBR Position: Q4 2025 in Review

Citadel Advisors sold out of Champions Oncology (CSBR) in Q4 2025, closing a stake of 16,326 shares — an estimated $106K sold.

Citadel Advisors first reported a position in CSBR in Q3 2016 and held it in 14 quarters. The position peaked at $280K in Q3 2022. 27 funds tracked by Wall St. Rank hold CSBR as of Q4 2025.

  • Citadel Advisors reported no remaining Champions Oncology position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 16,326 Champions Oncology shares in Q4 2025, an estimated $106K.
  • Citadel Advisors first reported a position in Champions Oncology in Q3 2016 and held it in 14 quarters.
  • Citadel Advisors's Champions Oncology position peaked at $280K in Q3 2022.
  • 27 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.